Clinical Trials Logo

Chronic Bronchitis clinical trials

View clinical trials related to Chronic Bronchitis.

Filter by:

NCT ID: NCT00250679 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Start date: October 2005
Phase: Phase 3
Study type: Interventional

To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).

NCT ID: NCT00245453 Withdrawn - Clinical trials for Pneumonia, Bacterial

Outpatient Registry Trial of Respiratory Tract Infections in Adults

Start date: October 2005
Phase: Phase 4
Study type: Interventional

To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.

NCT ID: NCT00245427 Completed - Sinusitis Clinical Trials

Outcomes of Patients Not Responding to Antibiotics in the Community

Start date: December 2005
Phase: N/A
Study type: Interventional

A study to report the outcomes of patients who fail to respond to beta-lactam and macrolide antibiotics in the community

NCT ID: NCT00233051 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Evaluating Genes in Sputum to Measure Drug Response in COPD

Start date: April 2003
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine whether analysis of genes in sputum is a useful noninvasive technique for measuring response to drugs in patients with COPD. We propose to use polymerase chain reaction to evaluate gene expression in induced sputum from adult current smokers with moderate COPD, adult former smokers with moderate COPD. This study is designed to determine whether changes in expression of previously-identified inflammatory markers in induced sputum can be detected in response to drug therapy in COPD and to evaluate potential differences in the expression of these markers in adult smokers with and without COPD. Pre- and post-treatment serum will be obtained to facilitate proteomic analysis of therapeutic response as well. Changes in sputum gene expression in response to treatment will be the primary outcome variable in this study. Secondary outcomes will include changes in lung function, as well as changes in induced sputum inflammation. These endpoints will be evaluated before and directly after 6 weeks of randomly-assigned treatment with either salmeterol xinafoate or fluticasone propionate/50mcg salmeterol xinafoate combination DPI bid. Endpoints will be re-evaluated following a 4 week wash-out period.

NCT ID: NCT00224198 Completed - Asthma Clinical Trials

Evaluation of the Lungs of Individuals With Lung Disease

Start date: January 2004
Phase: N/A
Study type: Observational

The purpose of this protocol is to obtain biologic materials from the blood and lungs from patients with lung disease in order to develop an understanding of the etiology and pathogenesis of these disorders. General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) patients with diseases of organs with known association with lung disease.

NCT ID: NCT00205647 Completed - Chronic Bronchitis Clinical Trials

Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

Start date: January 1997
Phase: Phase 2
Study type: Interventional

This is a randonmized, masked, placebo-controlled parallel group, clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine (NAC) and placebo on patient safety and on physical and transport properties of expectorated sputum. Patient sumptoms, quality of life and exacerbation will also be followed as well as pulmonary function testing and functional exercise capacity. We hypothesized that a prolongeed course of oral NAC favorably affects the morbidity of chronic bronchitis, particularly the incidence of acute exacerbations.

NCT ID: NCT00184977 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

COPD on Primary Care Treatment (COOPT)

Start date: December 1998
Phase: Phase 4
Study type: Interventional

The aim of this family practice based study is to determine the long-term treatment effects of two drugs that are presumed to modify the course and progression of chronic obstructive pulmonary disease (COPD), oral N-acetylcysteine and inhaled corticosteroids.

NCT ID: NCT00181207 Completed - COPD Clinical Trials

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

Start date: May 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to show that one form of mechanical airway clearance techniques, High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish exacerbations of COPD which will improve respiratory health status.

NCT ID: NCT00175565 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Inhaled Steroid Reduces Systemic Inflammation in COPD

Start date: January 2002
Phase: Phase 4
Study type: Interventional

Systemic inflammation is present in chronic obstructive pulmonary disease (COPD), which has been linked to cardiovascular morbidity and mortality. We determined the effects of oral and inhaled corticosteroids on serum markers of inflammation in patients with stable COPD.

NCT ID: NCT00153634 Completed - Cystic Fibrosis Clinical Trials

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Start date: March 2004
Phase: N/A
Study type: Interventional

This was a randomized multi-center clinical trial to compare the microbiological efficacy, clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P. aeruginosa sputum isolates to guide antibiotic selection for treatment of airway infection in clinically stable patients with CF.